# 1. Financial Performance ## A. Key Figures * **Operating Income:** **₹110.5 Cr** (Q2 FY26) · **EBITDA:** **₹7.5 Cr** (6.78% margin) · **Net Profit:** **₹10.5 Cr** (9.59% PAT margin) ## B. Revenue & Growth * **Pulp Price Stability:** Pulp prices remain largely stable with only **$50/ton reduction** in select grades; no broad-based decline observed. * **Realization Improvement:** Realizations up **~2%** due to higher MCC pricing, despite limited pass-through of pulp cost reductions. ## C. Margins & Profitability * **Margin Headwinds & Outlook:** Gross margin declined **170 bps YoY** due to elevated transportation costs post-fire; stabilization expected in **Q3 and Q4**. * **Exceptional Gain:** Q2 includes **₹7 Cr exceptional item** from reversal of excess provision (₹53 Cr out of ₹121 Cr) related to fire-related stock loss (actual loss: ₹66 Cr). * **Strategic Margin Initiatives:** Focus on portfolio optimization—phasing out **low-volume SKUs** and prioritizing high-value products to drive sustainable profitability. ## D. Balance Sheet * **Insurance Recovery Path:** Net fire impact is **₹47 Cr** (after ₹53 Cr reversal); company expects **~₹70 Cr total recovery**, including **₹51 Cr (fixed assets)**, **₹5 Cr (business interruption)**, and **₹65 Cr (stock claim)**. * **Promoter Stake Clarity:** **4% reduction** in promoter holding due to **repayment of loan against shares (LAS)**, not share sales; **no plans for further reduction** or increased pledging. * **Debt Capacity Planning:** Proposed **₹1,000 Cr debt approval** is for future flexibility—**not immediate drawdown**—to support expansion and working capital, with current limits at **₹200 Cr (~₹130 Cr utilized)** rising to **₹300–400 Cr**. * **Capital Structure Flexibility:** CAPEX and funding decisions remain **agnostic to equity or debt**, with options to refinance or offset via accruals; **promoters intend to participate in future issues**, potentially increasing stake. ## E. Cash Flow * **Working Capital Pressure:** DSO exceeds **100 days**, inventory held for **~60 days**, leading to a **120–130 day working capital cycle**; raw material overhang from pre-incident Hyderabad unit orders. * **Near-Term Liquidity Boost:** **Ad hoc insurance payout** of **~₹70 Cr** (including loss of profit) expected in **Q3**, providing cash flow relief. --- # 2. Product & Segment Performance ## A. Key Figures * **Revenue (Q2 FY):** **₹66.4 Cr** MCC · **₹13.17 Cr** O&M · **₹18.41 Cr** API * **Business Mix:** **75–80%** pharma/nutraceuticals · **80–90%** repeat customers * **Segment Contribution (Q2):** MCC **60%** (vs. 81% YoY) · O&M **12%** · API **17%** · Others **11%** * **Margins:** O&M **20–22%** · CCS projected **~30%** EBITDA ## B. MCC Business * **Pricing Resilience:** MCC realizations rose sequentially and YoY despite lower pulp costs, supported by **strong demand** and **persistent supply shortages** in the MCC market. * **Structural Shift:** MCC’s revenue share declined significantly YoY, enabling higher contributions from O&M and API, though this was largely due to **MCC’s own revenue contraction** rather than explosive growth in other segments. * **Customer Stickiness:** High repeat business (**80–90%**) underscores strong client relationships and product quality in a competitive excipient landscape. ## C. API & O&M Revenue * **O&M Margin Parity:** O&M maintains healthy margins of 20–22%, consistent with historical MCC levels, positioning it as a stable earnings contributor. * **API Growth Trajectory:** API now represents a **17% revenue share**, with management expecting **gradual expansion** despite current margin details not disclosed. * **Other Trade Outlook:** Non-core trade activities expected to stabilize at **5–6%** of total business, indicating limited strategic emphasis. ## D. CCS Development * **Strategic Expansion:** CCS plant on track for **Q3 FY27 commissioning**, with commercial production expected in **Oct–Nov FY26**, marking entry into high-value excipients. * **High-Margin Potential:** CCS projected to deliver **~30% EBITDA margins**, driven by **5x higher realizations than MCC**, making it a key value driver post-ramp-up. * **Polymer Portfolio Development:** Company has built a **coating portfolio in polymer-based excipients**, entering a space dominated by players like **Evonik**, though revenue remains negligible during sampling/approval phase. * **Long-Term Market Opportunity:** Global CCS demand projected at **$800–900 Mn by 2035**, while MCC market expected to reach **$4 Bn by 2034**, validating strategic positioning in growing excipient markets. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Civil Works Investment:** **₹150 Cr** across Dahej and Jhagadia plants * **MCC Expansion CAPEX:** **₹100 Cr** for 12,000 MTPA project · **₹60 Cr** planned for CCS * **Revenue Potential:** **₹250 Cr** peak revenue from new 12,000 MTPA MCC facility * Capacity Utilization: 82.69% Dahej · 81.33% Jhagadia · 82% overall (H1 FY26, ex-Hyderabad) * **Total Annual Capacity:** **18,000 MTPA** (current network) · expanding to **30,000 MTPA** MCC capacity post-expansion ## B. Facility Restoration * **Operational Resilience:** Seamless production shift from Hyderabad to Dahej and Jhagadia ensures uninterrupted supply, highlighting network flexibility and business continuity. * **Hyderabad Timeline:** Resumption pending regulatory approvals and safety compliance, with clarity expected by quarter-end; final decision awaits investigation findings. * **Orvakal Plans:** Expansion under evaluation for API or MCC projects, potentially concurrent with other CAPEX; announcement contingent on board approval. * **Phased CAPEX Execution:** Civil infrastructure completed upfront across sites to enable progressive machinery installation, aligning with industry best practices. ## C. Capacity Expansion * **MCC Scale-Up:** 12,000 MTPA expansion underway at Dahej SEZ, targeting commissioning by Q3 FY27, with ~50% capacity online in H1 FY27 to meet rising global demand. * **Accelerated Ramp-Up:** Dahej and Jhagadia operating at elevated utilization in second half to offset Hyderabad outage, supporting path to **~90% group-wide utilization by FY26 end**. ## D. Utilization Rates * **Near-Term Utilization Target:** Despite low H1 average, company on track to reach **~90% capacity utilization** by FY26 close, driven by internal capacity rebalancing and ramp-up momentum. * **Capacity Reallocation:** Full transfer of Hyderabad’s 6,000 MTPA output to Dahej and Jhagadia now underway in Q3/Q4 after Q2 delays due to enhanced safety reviews. --- # 4. Export & Geography Mix ## A. Key Figures * **Export Revenue Mix:** **55–60%** of total revenue (prior year) ## B. International Revenue * **Strategic Expansion:** Export footprint growing in MCC, with new value-added products set to enhance profitability in regulated markets. * **Regulatory Progress:** Nearly **nine dossiers** under review with EDQM, supporting entry into high-value European markets. * **Pricing Advantage:** Exports prioritized for CCS sales due to higher price realizations, with supply allocation favoring international markets. * **Mix Alignment:** CCS export sales mix expected to mirror MCC’s strong international orientation. ## C. Regulated Markets * **Competitive Moat:** Chinese MCC suppliers remain non-competitive in regulated markets, preserving Sigachi’s advantage. * **Government Support:** Ongoing invitations from multiple states to establish new plants reinforce favorable policy tailwinds. --- # 5. R&D & Regulatory Progress ## A. Regulatory & Project Milestones * **Headline:** Advancing CEP filings for **four APIs** to strengthen presence in regulated markets, with approvals expected over the next two to three quarters. * **Headline:** Regulatory approval clarity anticipated by **Q3**, pending final clearances, de-risking near-term commercialization plans. * **Headline:** Environmental clearance for Orvakal facility expected within **30 days**, removing a key operational hurdle. ## B. R&D Center Operations * **Headline:** New Hyderabad API R&D Center now fully operational, enabling integrated development, faster scale-up, and improved compliance readiness. * **Headline:** Center to accelerate innovation and product pipeline, reinforcing strategic shift toward becoming a **fully integrated pharmaceutical company**. --- # 6. Risks & Operational Factors ## A. Key Figures * **Fire-Related Provision:** **₹121 Cr** (fixed assets, stock, compensation, GST) * Insurance Claims Filed: ₹70 Cr (fixed assets ₹51.48 Cr, stock ₹7.66 Cr, loss of profit ₹16.5 Cr) * **Expected Net Cost Post-Insurance:** **~₹40 Cr** (subject to government support) * Fixed Asset Insurance Recovery: ₹51.48 Cr expected in Q3 FY26 * **Business Interruption Claim:** **12-month period**, expected in **Q4 or year-end** ## B. Fire Incident Impact * **Controlled Incident Response:** Preliminary investigation identifies a localized dust explosion at Hyderabad facility; government probe ongoing, but operations in other plants remain unaffected. * **Business Continuity Maintained:** Despite a production shortfall from one unit shutdown, critical customer supply was prioritized, and timelines communicated for others to manage disruptions. * **Comprehensive Safety Reinforcement:** Post-incident, full safety re-audits completed at Dahej and Jhagadia; enhanced protocols, training, and accountability systems now in place across all four plants. * **Full Provisioning & Recovery Path:** All fire-related losses fully provided for in H1; **no further provisions** expected, with **₹48 Cr fixed asset claim** due in Q3 and business interruption recovery anticipated by year-end. * **Human Capital & Cost Mitigation:** Interim compensation and full medical coverage provided; company bearing **portion of worker compensation** beyond insurance, while actively seeking **government support** to reduce net outlay. ## C. Supply Chain Disruptions * **Stable Competitive Landscape:** No pricing pressure from Chinese MCC suppliers observed domestically or in exports; **no volume-driven price cuts** taken in FY26. * **High Customer Stickiness:** Pharma clients face significant barriers to switching due to **regulatory validation**, **API cost sensitivity**, and reliance on **proven track records**, insulating Sigachi from new entrants. * **Structural Supply Rigidity:** Customer approvals are site-specific, making reallocation across facilities or suppliers infeasible without revalidation, reinforcing Sigachi’s entrenched position. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Guidance (FY26):** **₹575 Cr** (minimum target) * **Capacity Expansion Revenue Contribution:** **₹250 Cr** (at full capacity, starting FY27) ## B. Revenue Forecast * **Sustained Growth Trajectory:** Expects consistent and sustainable revenue expansion over the next 2–3 years, driven by excipients, APIs, and O&M services, underpinned by capacity scale-up and improved product mix. * **Commercial Ramp-Up Timing:** Polymer excipients sales to commence only upon client formulations reaching commercial production, with **revenue contribution expected to follow progressively**. * **Near-Term Outlook:** Anticipates performance recovery in Q3 and Q4, with return to regular growth momentum thereafter despite short-term disruptions. * **API Segment Stability:** FY26 revenue outlook for APIs remains unchanged, reflecting confidence in execution and demand visibility. ## C. Margin Expectations * **Value-Accretive Scaling:** Focus on high-value segments and regulated markets continues, supported by investments in compliance, R&D, and infrastructure to drive long-term margin resilience. * **Operational Discipline:** Emphasis on safety, execution rigor, and project tracking ensures foundation for sustainable profitability despite temporary facility disruption.